Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01059448 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AMG 827 in Subjects With RA
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 211
- Enrollment target
NCT01059448 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 211 participants.
The verdict
NCT01059448, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 211 participants
- Enrollment target
Study Summary
This is an extension study for subjects who participated in Protocol 20090061 (NCT00950989). All subjects in this study will receive a 210mg injection of AMG827 for treatment for their Rheumatoid Arthritis for up to 5 years.
Interventions
- DRUG AMG 827
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2010-06-03 |
| Est. Completion | 2011-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01059448
The ClinicalTrials.gov registry entry for NCT01059448 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 827 is the first listed.
NCT01059448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01059448 about?
NCT01059448 is a clinical study titled "Safety and Efficacy of AMG 827 in Subjects With RA". This is an extension study for subjects who participated in Protocol 20090061 (NCT00950989). All subjects in this study will receive a 210mg injection of AMG827 for treatment for their Rheumatoid Arthritis for up to 5 years.
What is the current status of trial NCT01059448?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 211 participants. The study started on 2010-06-03. Estimated completion is 2011-04-05.
What interventions are being tested in trial NCT01059448?
The interventions under investigation include: AMG 827 (DRUG).
Who is sponsoring clinical trial NCT01059448?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.